# A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections

> **NCT05544916** · PHASE3 · COMPLETED · sponsor: **Valenta Pharm JSC** · enrollment: 260 (actual)

## Conditions studied

- Influenza
- Respiratory Viral Infection

## Interventions

- **DRUG:** XC221
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05544916
- **Lead sponsor:** Valenta Pharm JSC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-05
- **Primary completion:** 2023-02-01
- **Final completion:** 2023-05-04
- **Target enrollment:** 260 (ACTUAL)
- **Last updated:** 2023-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05544916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05544916, "A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05544916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*